SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guilford (GLFD) - Steadily Rising

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: SteveG who wrote (75)8/25/1997 8:08:00 PM
From: Miljenko Zuanic   of 496
 
Steve:

Your explanation is simplified, but for now (until we see data prom primate study) let put this aside. Potential problem is in *therapeutic window* of 100 fold Ki difference for rotomase inhibitor related to calcineurine inhibitor. This window can be easily passed and possibility are that drug my have side effects.

>>I would think that FKBP/FK-506 and any derivatives (which the NIP ligands are) would be structurally similar. Do you think that VRTX's rotamase inhibitors also have non-immunosuppresant neuroimmunophilic properties?<<

Yes. VRTX patent (5,654,332) cover broad class of the N-1,2-diketo-(Y)-(2S)-pyrrolidine-(X)- carboxylate derivatives which are very potent rotomase inhibitors (Ki~1-20 nM) with significant neurite outgrowth capability over control, alone or in combination with NGF (~50% increase).

Does anyone know basic structures for other GLFD NIP ligands? Their patent (5,614,547) cover only one class of the NIP ligands: N-(3,3-dimethyl-1,2-dioxopentyl)-(2S)-pyrrolidine-carboxylate-(X).

Actually, I was surprised by strong numbers in AMGN agreement accounting that they will have strong competitor in VRTX and their collaborator (?) for the some molecules and therapeutic targets. This two abstracts show how seriously VRTX study FKBP-L12 complex with FK 506.

ncbi.nlm.nih.gov
ncbi.nlm.nih.gov

Regards,

mz
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext